Ketim Therapeutics enters agreements with Mater Research

Ketim Therapeutics has partnered with Mater Research to advance predictive biomarker research for perinatal depression using Queensland Family Cohort data. Affecting 1 in 5 women, perinatal depression poses serious risks, yet early detection remains a challenge. By identifying blood-based biomarkers, Ketim’s AI-driven technology aims to equip clinicians with a powerful early detection tool for personalised care. This collaboration strengthens Ketim’s mission to bridge research and clinical application, setting a new standard for maternal mental health diagnostics.